Clinical Trial

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Study acronym: ATTACH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-16.
Trial Details
NCT Number NCT07239245
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Enrollment 30 participants
Start Date 2025-11-12
Primary Completion 2027-11-10 (estimated)
Study Completion 2030-11-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-25